HER2‐low BC should deserve more attention than HER2‐zero BC, especially in HR‐negative BC, due to larger proportion, less clinical heterogeneity, better prognosis, and less susceptibility to risk factors. This evidence concerns the gene ERBB2 and breast cancer.